Abstract
Clonal hematopoiesis (CH) is a form of age-related somatic mosaicism. CH encompasses both clonal events with recognizable leukemic driver mutations, such as CH of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs), as well as clonal states without clear driver mutations. Stacey et al. identify cases of CH from whole genome sequencing (WGS) data in a subset of 130,709 UK Biobank (UKB) participants and in 45,510 individuals from an Icelandic cohort. They report that CH is not associated with cardiovascular disease (CVD) and posit that the multiple prior CH studies did not fully account for smoking-related confounding. We find that the conclusion reached by Stacey et al. is specific to their particular CH definition which groups well-established and clinically meaningful CH subtypes together despite evidence from multiple previous reports that distinct forms of CH have distinct phenotypic consequences. We show that (1) the CHIP/ CVD association in the UK Biobank is not confounded by smoking and (2) CH subtypes which Stacey et al. have lumped together have heterogenous associations with CVD. We suggest that Stacey et al.’s failure to identify an association between CHIP and CVD is perhaps related to methodologic differences compared to prior reports.
Competing Interest Statement
S.J. is on advisory boards for Novartis, AVRO Bio, and Roche Genentech, is a paid consultant for Foresite Labs, reports speaking fees/honorarium from GSK, and is on the scientific advisory board to Bitterroot Bio. P.N. reports grants support from Amgen, Apple, and Boston Scientific, and is a paid consultant to Apple and Foresite Labs. A.G.B. is a paid consultant to Foresite Labs. S.J., A.G.B., and P.N. are co-founders, equity holders, and on the scientific advisory board of TenSixteen Bio. Other co-authors declare no competing interests.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to the UK Biobank dataset was provided under application 43397. Local approval for secondary analyses of the data was obtained from the Vanderbilt University Medical Center institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
UK Biobank data is available to all registered researchers.
